Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti‐Tumor Activity in a Preclinical Model of Non‐Hodgkin’s LymphomaKathryn Logronio, M. F. Kotturi, M. K. Leabman et al.|Hematological Oncology|2023Cited by 2
Abstract 4179: High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killingKevin C. Hart, Maya F. Kotturi, Kathryn Logronio et al.|Cancer Research|2022Cited by 1